Repligen Corp reports results for the quarter ended December 31 - Earnings Summary

• Repligen Corp RGEN.OQ reported quarterly adjusted earnings of 44 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 33 cents. The mean expectation of nineteen analysts for the quarter was for earnings of 41 cents per share. Wall Street expected results to range from 35 cents to 46 cents per share.

• Revenue rose 7.6% to $167.55 million from a year ago; analysts expected $167.67 million.

• Repligen Corp's reported EPS for the quarter was a loss of 60 cents​.

• The company reported a quarterly loss of $33.87 million.

• Repligen Corp shares had risen by 4.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Repligen Corp is $190.00

This summary was machine generated from LSEG data February 20 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)